Procter & Gamble Operating Cash Flow increased by 8.5% to $5.41B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 25.7%, from $4.30B to $5.41B. Over 4 years (FY 2021 to FY 2025), Operating Cash Flow shows relatively stable performance with a -0.8% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates strong operational efficiency and cash generation, while a decrease may signal operational challenges or issues with working capital management.
This metric represents the total cash generated or consumed by a company's core business operations during a specific pe...
Standard across all industries; peers in the medical device and diagnostics sector typically maintain high conversion ratios of net income to operating cash flow.
net_cash_from_operating| Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.12B | $4.64B | $3.00B | $5.37B | $3.71B | $4.07B | $5.93B | $1.50B | $5.34B | $4.90B | $4.22B | $4.97B | $5.75B | $4.30B | $6.08B | $2.45B | $4.99B | $5.41B |
| QoQ Change | — | +12.7% | -35.4% | +78.8% | -30.8% | +9.6% | +45.8% | -74.7% | +255.4% | -8.2% | -13.9% | +17.6% | +15.9% | -25.2% | +41.3% | -59.7% | +103.3% | +8.5% |
| YoY Change | — | — | — | — | -9.9% | -12.3% | +97.7% | -72.0% | +43.8% | +20.5% | -28.8% | +230.3% | +7.7% | -12.3% | +43.9% | -50.6% | -13.4% | +25.7% |